Location History:
- Middletown, NY (US) (2020 - 2022)
- Troy, NY (US) (2023)
Company Filing History:
Years Active: 2020-2023
Title: Kevin Li - Innovator in Biosynthetic Heparin
Introduction
Kevin Li is a prominent inventor based in Middletown, NY (US), known for his significant contributions to the field of biosynthetic heparin. With a total of three patents to his name, he has made remarkable advancements in the synthesis and modification of heparin, a crucial anticoagulant used in medical applications.
Latest Patents
One of Kevin Li's latest patents focuses on the synthesis of biosynthetic heparin, which may be bioequivalent to porcine USP Heparin Sodium. This innovative synthesis involves three intermediates starting from heparosan. Another notable patent is for the enzymatic preparation of increased anticoagulant bovine-sourced heparin. This patent discloses a heparin structure with enhanced anticoagulant activity, achieved through an enzymatic reaction that adds sulfuryl groups to the heparin sample. The modified heparin exhibits an anti-FXa activity and an anti-FIIa activity greater than about 180 U/mg, making it a viable alternative to porcine intestinal heparin.
Career Highlights
Kevin Li is affiliated with Rensselaer Polytechnic Institute, where he continues to engage in groundbreaking research. His work has positioned him as a key figure in the development of synthetic alternatives to traditional heparin, addressing the need for safer and more effective anticoagulant therapies.
Collaborations
Some of Kevin Li's notable coworkers include Makoto Hirakane and Li Fu, who have collaborated with him on various research projects related to heparin synthesis and modification.
Conclusion
Kevin Li's innovative work in the field of biosynthetic heparin showcases his dedication to advancing medical science. His patents reflect a commitment to improving anticoagulant therapies, which can have a significant impact on patient care.